---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-059381"
form_type: "8-K"
ticker: "KYNB"
cik: "0000921299"
company_name: "KYNTRA BIO, INC."
filed_at: "2023-11-06T23:59:59+00:00"
generated_at: "2026-06-08T21:46:56.650190+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# FibroGen Q3 revenue up 155% to $40.1M; roxadustat China sales up 31%

## Summary
- Net loss of $63.6M ($0.65 loss per share) vs $91.7M ($0.98) YoY; restructuring charge of $12.6M.
- Roxadustat net product revenue in China reached $29.4M, up 69% YoY; total China sales $77.1M (up 31%), driven by 37% volume growth.
- Annualized cost reduction of $120M implemented; cash of $283.0M expected to fund operations into 2026.
- Pamrevlumab LAPIS Phase 3 topline data expected Q1 2024; PanCAN Phase 2/3 data in 1H 2024.
- sNDA for roxadustat in chemotherapy-induced anemia accepted in China; approval decision mid-2024.

## SEC filing metadata
- accession: 0000950170-23-059381
- form_type: 8-K
- ticker: KYNB
- cik: 0000921299
- company_name: KYNTRA BIO, INC.
- filed_at: 2023-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921299/000095017023059381/0000950170-23-059381-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921299/000095017023059381/fgen-20231106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-059381
- JSON: https://secwatch.observer/filing/0000950170-23-059381.json
- Plain text: https://secwatch.observer/filing/0000950170-23-059381.txt

## Key facts
- Earnings Releases
  KYNTRA BIO, INC. reported third quarter 2023 results: revenue Total revenue for the third quarter of 2023 was $40.1 million, net income Net loss for the third quarter of 2023 was $63.6 million, or $0.65 net loss per basic and diluted share, EPS $0.65 net loss per basic and diluted share.
  - Period: third quarter 2023
  - Revenue: Total revenue for the third quarter of 2023 was $40.1 million
  - Net income: Net loss for the third quarter of 2023 was $63.6 million, or $0.65 net loss per basic and diluted share
  - EPS: $0.65 net loss per basic and diluted share
  - Result: reported results
  source text: FibroGen Reports Third Quarter 2023 Financial Results
  evidence_url: https://www.sec.gov/Archives/edgar/data/921299/000095017023059381/0000950170-23-059381-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.